Diagnóstico y tratamiento | 13 MAY 13

Enfermedad de Paget ósea

Este es un trastorno común caracterizado por áreas focales donde la remodelación ósea está aumentada y desorganizada; puede afectar a uno o más huesos.
Autor: Dres. Stuart H. Ralston N Engl J Med 2013;368:644-50.
INDICE:  1. Artículo | 2. Referencias

1. Siris ES, Roodman GD. Paget’s disease of bone. In: Rosen C, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. Hoboken, NJ: Wiley, 2012:335-43.
2. van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71.
3. Takata S, Hashimoto J, Nakatsuka K, et al. Guidelines for diagnosis and management of Paget’s disease of bone in Japan. J Bone Miner Metab 2006;24:359-67.
4. Joshi SR, Ambhore S, Butala N, et al. Paget’s disease from Western India. J Assoc Physicians India 2006;54:535-8.
5. Mays S. Archaeological skeletons support a northwest European origin for Paget’s disease of bone. J Bone Miner Res 2010;25:1839-41.
6. Rebel A, Malkani K, Basle M, Bregeon C, Patezour A, Filmon R. Ultrastructural characteristics of osteoclasts in Paget’s disease. Rev Rhum Mal Osteoartic 1974;41:767-71. (In French.)
7. Chung PY, Van Hull W. Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 2012;41:619-41.
8. Daroszewska A, van’t Hof RJ, Rojas JA, et al. A point mutation in the ubiquitin associated domain of SQSMT1 is sufficient to cause a Paget’s disease-like disorder in mice. Hum Mol Genet 2011;20:2734-44.
9. Roodman GD, Windle JJ. Paget disease of bone. J Clin Invest 2005;115:200-8.
10. Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int 2012;91:97-113.
11. Poór G, Donath J, Fornet B, Cooper C. Epidemiology of Paget’s disease in Europe: the prevalence is decreasing. J Bone Miner Res 2006;21:1545-9.
12. Albagha OME, Wani S, Visconti MR, et al. Genome-wide association identifies three new susceptibility loci for Paget’s disease of bone. Nat Genet 2011;43:685-9.
13. Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 2010;42:520-4.
14. Tiegs RD, Lohse CM, Wollan PC, Melton LJ. Long-term trends in the incidence of Paget’s disease of bone. Bone 2000;27:423-7.
15. Galbraith HJB, Evans EC, Lacey J. Paget’s disease of bone — a clinical and genetic study. Postgrad Med J 1977;53:33-9.
16. Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone 2009;44:431-6.
17. Eekhoff ME, van der Klift M, Kroon The New England Journal of Medicine HM, et al. Paget’s disease of bone in the Netherlands: a population-based radiological and biochemical survey — the Rotterdam Study. J Bone Miner Res 2004;19:566-70.
18. Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone 2004;35:224-30.
19. Schwindinger WF, Levine MA. Mc-Cune-Albright syndrome. Trends Endocrinol Metab 1993;4:238-42.
20. Nguyen MT, Borchers A, Selmi C, Naguwa SM, Cheema G, Gershwin ME. The SAPHO syndrome. Semin Arthritis Rheum 2012;42:254-65.
21. Altman RD. Musculoskeletal manifestations of Paget’s disease of bone. Arthritis Rheum 1980;23:1121-7.
22. Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget’s disease of bone. Am J Med 1974;56:592-603.
23. Redden JF, Dixon J, Vennart W, Hosking DJ. Management of fissure fractures in Paget’s disease. Int Orthop 1981;5:103-6.
24. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston SH, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget’s disease. Lancet 1984;1:821-4.
25. Harinck HIJ, Papapoulos SE, Blanksma HJ, Moolenar AJ, Vermeij P, Bijvoet OLM. Paget’s disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). Br Med J (Clin Res Ed) 1987;295:1301-5.
26. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget’s disease of bone. Am J Med 1999;106:513-20.
27. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget’s disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996;101:341-8.
28. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 2005;353:898-908.
29. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget’s disease of bone. J Clin Endocrinol Metab 1996;81:961-7.
30. Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget’s disease of bone. Bone 2004;34:747-54.
31. Gallacher SJ, Ralston SH, Patel U, Boyle IT. Side effects of pamidronate. Lancet 1989;2:42-3.
32. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 2010;95:4380-7.
33. Silverman SL, Kriegman A, Goncalves J, Kianifard F, Carlson T, Leary E. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporos Int 2011;22:2337-45.
34. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010;86:421-35.
35. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37. [Errata, N Engl J Med 2011;365:1551, 2012;367:582.]
36. Kilcoyne A, Heffernan EJ. Atypical proximal femoral fractures in patients with Paget disease receiving bisphosphonate therapy. AJR Am J Roentgenol 2011;197:W196-W197.
37. Woodhouse NJ, Bordier P, Fisher M, et al. Human calcitonin in the treatment of Paget’s bone disease. Lancet 1971;1:1139-43.
38. Singer FR. Clinical efficacy of salmon calcitonin in Paget’s disease of bone. Calcif Tissue Int 1991;49:Suppl 2:S7-S8.
39. Schwarz P, Rasmussen AQ, Kvist TM, Andersen UB, Jørgensen NR. Paget’s disease of the bone after treatment with denosumab: a case report. Bone 2012;50:1023-5.
40. Parvizi J, Klein GR, Sim FH. Surgical management of Paget’s disease of bone. J Bone Miner Res 2006;21:Suppl 2:P75-P82.
41. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget’s disease of bone. J Bone Miner Res 2001;16:1379-87.
42. Goldhahn J, Féron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int 2012;90:343-53.
43. Sharma H, MacDuff E, Jane MJ, Reid R. Sarcomatous change in the pagetoid tibiae. Int Orthop 2005;29:319-25.
44. Ravault A, Meunier PJ. Long-term follow-up of 88 patients with Paget’s disease treated by discontinuous course of lowdose disodium etidronate. Rev Rhum Mal Osteoartic 1989;56:293-302. (In French.)
45. Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s disease of bone. J Bone Miner Res 2010;25:20-31.
46. Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remissions in Paget disease — data to 6.5 years. J Bone Miner Res 2011;26:2261-70.
47. Selby PL, Davie MW, Ralston SH, Stone MD. Guidelines on the management of Paget’s disease of bone. Bone 2002;31:366-73. [Erratum, Bone 2002;31:437.]



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2017